☆ 4.7 Review

Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2024)

Related references

Note: Only part of the references are listed.

Article Oncology

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Thierry Andre et al.

Summary: The NEONIPIGA study found that perioperative platinum-based chemotherapy is the standard treatment for resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. However, the efficacy of perioperative chemotherapy in gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) remains debatable. This study showed that neoadjuvant nivolumab-based therapy is feasible, associated with no unexpected toxicity, and has a high pathological complete response (pCR) rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Targeting GPC3(high) cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer

Dinuo Li et al.

Summary: Cancer-associated fibroblasts (CAFs) play a significant role in the tumour microenvironment of gastric cancer (GC), but their role in immunotherapy is not well understood. This study identified a subgroup of CAFs in advanced GC with up-regulated Glypican-3 (GPC3), which was associated with poor prognosis and decreased response to PD-1 therapy. Targeting GPC3(high) CAFs sensitized the PD-1 blockage therapy in GC. These findings suggest that GPC3 expression in CAFs is a critical prognostic biomarker and may be a potential target for improving immunotherapy in GC.

ANNALS OF MEDICINE (2023)

Add to Collection

Article Oncology

Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-?B-IL-6 axis of tumor-associated macrophages

Boxuan Zhou et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

CREBZF mRNA nanoparticles suppress breast cancer progression through a positive feedback loop boosted by circPAPD4

Boxuan Zhou et al.

Summary: This study firstly illustrated that the circPAPD4/miR-1269a/CREBZF/STAT3/ADAR1 positive feedback loop mediated breast cancer progression, and delivering CREBZF mRNA nanoparticles suppressed breast cancer progression in vitro and in vivo, which might provide novel insights into therapeutic strategies for breast cancer.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Immunology

PKM2/STAT1-mediated PD-L1 upregulation on neutrophils during sepsis promotes neutrophil organ accumulation by serving an anti-apoptotic role

Yinjiaozhi Li et al.

Summary: This study identified the upregulation of programmed death ligand-1 (PD-L1) on neutrophils and the anti-apoptotic effect of upregulated PD-L1 during sepsis, which may lead to increased neutrophil accumulation in the lungs and liver. The glycolytic enzyme pyruvate kinase M2 (PKM2) was found to promote PD-L1 expression through interaction with and activation of signal transducer and activator of transcription 1 (STAT1). These findings suggest that PKM2 and PD-L1 could be potential therapeutic targets.

JOURNAL OF INFLAMMATION-LONDON (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Relationships of tumor differentiation and immune infiltration in gastric cancers revealed by single-cell RNA-seq analyses

Xin Zhou et al.

Summary: The study revealed the heterogeneity of gastric cancers and the relationship between differentiation status of cancer cells and tumor immune microenvironments. PDGC showed enrichment of genes related to epithelial-mesenchymal transition (EMT) program. DGC tended to be immune-rich type while PDGC tended to be immune-poor type, and this was associated with the density of tumor-infiltrating CD8(+) T cells. Along the trans-differentiation from DGC to NEC, interferon-related pathways were downregulated, leading to enhanced immune evasion.

CELLULAR AND MOLECULAR LIFE SCIENCES (2023)

Add to Collection

Review Oncology

Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis

Juan Ren et al.

Summary: This study found no prognostic effects of PD-L1 and TILs in gastric cancer patients.

CLINICAL & TRANSLATIONAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients

Hyun Cheol Chung et al.

Summary: The study compared pembrolizumab with paclitaxel as second-line therapy for Asian patients with advanced PD-L1-positive gastric/GEJ cancer. The results showed no significant difference in overall survival and progression-free survival between the two drugs, but pembrolizumab was well-tolerated in this patient population.

CANCER (2022)

Add to Collection

Article Oncology

Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast

Yusuke Nakamura et al.

Summary: By suppressing cancer-associated fibroblasts (CAFs), Tranilast improved the immunosuppressive microenvironment in a mouse PM model and showed potential as a candidate drug for PM treatment.

GASTRIC CANCER (2022)

Add to Collection

Article Oncology

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

Kensei Yamaguchi et al.

Summary: This postmarketing surveillance study assessed the real-world safety and effectiveness of nivolumab as salvage therapy in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer, showing consistent results with previous studies and a potential improvement in tumor response rates.

GASTRIC CANCER (2022)

Add to Collection

Article Oncology

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon-Koo Kang et al.

Summary: This study investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy for HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer, showing a significant improvement in progression-free survival but not overall survival in Asian patients. The combination therapy may potentially serve as a new first-line treatment option for these patients.

LANCET ONCOLOGY (2022)

Add to Collection

Correction Oncology

Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression (vol 7, 41, 2018)

Furong Wang et al.

ONCOGENESIS (2022)

Add to Collection

Article Oncology

Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection

Xiuxing Chen et al.

Summary: The study suggests that preoperative exosomal PD-L1 (exoPD-L1) and soluble PD-L1 (sPD-L1) levels are associated with the survival of colorectal liver metastasis patients, and are related to T cell infiltration at liver metastases. Tracking exoPD-L1 and sPD-L1 levels could help monitor disease status and detect early recurrence.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment

Gerd Jomrich et al.

Summary: This study investigated the impact of neoadjuvant chemotherapy on the expression of PD-1 and PD-L1 in adenocarcinomas of the gastroesophageal junction. The results showed a significant increase in PD-1 expression and a decrease in PD-L1 expression after neoadjuvant therapy. These findings suggest that the combined use of cytotoxic chemotherapy and PD-1 axis blockade may be beneficial for patients with adenocarcinomas of the gastroesophageal junction.

EJSO (2022)

Add to Collection

Article Oncology

Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells

Xiang Li et al.

Summary: This study found that elevated pretherapeutic serum interleukin-8 (sIL-8) levels in patients with gastric cancer are associated with lymph node metastasis and poor prognosis. Gastric cancer-associated fibroblasts (CAFs) were identified as the main producers of IL-8, which in turn up-regulates PD-1 expression in CD8(+) T cells, leading to immune suppression and promoting lymph node metastasis in gastric cancer.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Charles S. Fuchs et al.

Summary: In this long-term analysis, second-line pembrolizumab did not significantly improve overall survival but was associated with higher 24-month OS rates than paclitaxel in the CPS>=1 population. Pembrolizumab also increased overall survival benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer treatment-related adverse events (TRAEs) compared to paclitaxel.

GASTRIC CANCER (2022)

Add to Collection

Article Oncology

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

Hirotaka Hasegawa et al.

Summary: Neoadjuvant nivolumab monotherapy is feasible and safe for resectable gastric cancer, and can induce a major pathologic response in certain patients.

GASTRIC CANCER (2022)

Add to Collection

Review Medicine, General & Internal

The current management and biomarkers of immunotherapy in advanced gastric cancer

Xiaojing Chang et al.

Summary: This study summarizes the current treatment and advances of immune checkpoint inhibitors in the advanced stage of gastric carcinoma (GC). Nivolumab and pembrolizumab have been recommended as treatment options for advanced GC. Other immune checkpoint inhibitors have also shown promising efficacy. PD-L1, MSI-H, EBV, and TMB status may serve as potential biomarkers for evaluating the response to immune checkpoint inhibitors in GC.

MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer

Dan-Dan Shen et al.

Summary: The expression of LSD1 is significantly elevated in gastric cancer patients and is associated with PD-L1 expression. LSD1 inhibits the response of T cells in the gastric cancer microenvironment by inducing the accumulation of PD-L1 in exosomes. Exosomes can also serve as vehicles for LSD1 to regulate T cell immunity in other cancer cells.

MOLECULAR CANCER (2022)

Add to Collection

Article Oncology

Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer

Nicole E. James et al.

Summary: This study compared the expression levels of immune co-stimulatory and co-inhibitory receptors in high grade serous ovarian cancer (HGSOC) and found that TIM-3 and OX40 were the most abundant receptors. OX40 was also strongly associated with improved patient survival.

ONCOLOGY LETTERS (2022)

Add to Collection

Article Multidisciplinary Sciences

Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment

Zhaoting Li et al.

Summary: This study reports a method to enhance the effectiveness of anti-tumor immunotherapy by locally depleting tumor-associated macrophages (TAMs) using a hydrogel reservoir. TAMs are depleted by releasing the colony-stimulating factor 1 receptor (CSF1R) inhibitor Pexidartinib and delivering anti-PD-1 antibody-conjugated platelets locally and systemically, effectively inhibiting post-surgery tumor recurrence.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Oncology

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer

Yuezong Bai et al.

Summary: In this study, an efficient next-generation sequencing (NGS) based algorithm was developed and validated for detecting Epstein-Barr virus (EBV) infection in gastric cancer (GC). EBV infection was found to be an independent predictive factor for immune checkpoint blockade (ICB) efficacy in GC, and CTLA-4, tumor mutational burden (TMB), and SMARCA4 mutation were identified as potential predictive biomarkers for ICB efficacy in EBV-associated GC (EBVaGC).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Haiping Jiang et al.

Summary: This study evaluated the efficacy of sintilimab plus CapeOx as a neoadjuvant regimen for patients with advanced resectable G/GEJ adenocarcinoma. The results showed a promising pathological complete response rate and good safety profile, suggesting that this combination regimen could be a new option for patients with locally advanced, resectable G/GEJ adenocarcinoma.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

Yoon-Koo Kang et al.

Summary: Retrospective studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors (ICIs). However, this study comparing nivolumab +/- ipilimumab versus placebo in patients with gastric or gastroesophageal junction cancer, and small cell lung cancer, did not find an increased rate of progression associated with ICI treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Multidisciplinary Sciences

Liver tumour immune microenvironment subtypes and neutrophil heterogeneity

Ruidong Xue et al.

Summary: This study used single-cell RNA sequencing analysis to investigate the heterogeneity of the tumour immune microenvironment (TIME) in liver cancer. The researchers identified five TIME subtypes and found that tumour-associated neutrophil (TAN) populations enriched in the myeloid-cell-enriched subtype were associated with an unfavourable prognosis. They also demonstrated that CCL4(+) TANs can recruit macrophages and that PD-L1(+) TANs can suppress T cell cytotoxicity. Mouse models confirmed the pro-tumour phenotypes of TANs. This study provides insights into the immunosuppressive functions of TANs and highlights their potential as targets for immunotherapies.

NATURE (2022)

Add to Collection

Article Oncology

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma

Zhihao Lu et al.

Summary: In patients with gastroesophageal adenocarcinoma, the presence of PD-L1 positivity, IFNγ-related gene signature, and high tumor mutational burden (TMB) were associated with clinical benefit from tislelizumab. On the other hand, hyperamplification (HA) was associated with worse clinical outcomes. Combining PD-L1 positivity with the absence of hyperamplification may help identify patients who are more likely to benefit from PD-1 blockade.

GASTRIC CANCER (2022)

Add to Collection

Article Oncology

Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report

Jinyu Xiang et al.

Summary: This case is the first report of successful treatment of AFPGC with tislelizumab combined with apatinib, suggesting a highly effective and tolerable therapeutic strategy in microsatellite-stabilized AFPGC patients.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer

Choong-kun Lee et al.

Summary: This study evaluated the efficacy and safety of a quadruplet regimen as first-line therapy for unresectable or metastatic HER2-positive advanced gastric cancer. The results showed durable efficacy and safety for patients treated with this regimen.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Oncology

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial

Yuping Yin et al.

Summary: The combination of PD-1 inhibitor tislelizumab with S-1 plus oxaliplatin (SOX) showed promising application potential in patients with advanced G/GEJ cancer, with a predictive model to accurately evaluate the therapeutic response of this scheme.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Hongzhen Cai et al.

Summary: Gastric cancer is a global health concern with high morbidity and mortality rates. Immunotherapy, targeting molecules such as PD-1, has become a first-line option for certain conditions, aiming to activate T cells and improve treatment efficacy.

BIOMARKER RESEARCH (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment

Boxi Kang et al.

Summary: By analyzing bulk and single-cell RNA sequencing data from 24 treatment-naive gastric cancer patients, this study identified 81 well-defined cell types in the gastric cancer tumor microenvironment (TME). Activated fibroblasts and endothelial cells were found to be overrepresented in tumors, while immunosuppressive myeloid cell subsets and regulatory T cells were associated with worsened prognosis and lack of response to anti-PD1 treatment. Conversely, a subset of IFN-activated T cells and HLA-II expressing macrophages were linked to treatment response and increased overall survival.

GENOME BIOLOGY (2022)

Add to Collection

Article Oncology

Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody

Lin Zhang et al.

Summary: Tislelizumab, an anti-PD-1 antibody, has demonstrated anti-tumor effects in various solid tumors and has received approvals in China for several indications. It has an acceptable safety profile and economic advantage compared to other PD-1 inhibitors, making it a promising tool for clinical oncologists.

CANCER CONTROL (2022)

Add to Collection

Article Oncology

Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer

Kohei Yamashita et al.

Summary: The study found that trastuzumab can upregulate PD-L1 expression on gastric cancer cells through interaction with NK cells. These results suggest clinical implications in the assessment of the predictive significance of PD-L1 expression for PD-1 inhibitors.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Advances in clinical immunotherapy for gastric cancer

Kexin Li et al.

Summary: Gastric cancer is a highly malignant cancer with increasing incidence worldwide, ranking among the top five malignant tumors in terms of incidence and mortality. Immunotherapy, as a breakthrough in cancer treatment, has shown to be effective in gastric cancer treatment, especially when used in combination with other modalities.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Add to Collection

Article Gastroenterology & Hepatology

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer

Camille Evrard et al.

Summary: The poor overall survival of patients with gastric or gastro-oesophageal junction adenocarcinomas has prompted research into first-line and second-line chemotherapy regimens, as well as the combination of immune checkpoint inhibitors with chemotherapy. Results have been mixed, highlighting the ongoing challenge in treating these types of tumors.

DIGESTIVE AND LIVER DISEASE (2021)

Add to Collection

Review Oncology

MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma

Daniel V. T. Catenacci et al.

Summary: This study describes the design and rationale of a clinical trial evaluating the use of margetuximab plus retifanlimab or margetuximab plus tebotelimab in unresectable metastatic/locally advanced gastric/gastroesophageal junction adenocarcinoma as first-line therapy. Primary endpoints include objective response rate, overall survival, and safety/tolerability.

FUTURE ONCOLOGY (2021)

Add to Collection

Review Oncology

Regulation of PD-L1 expression in the tumor microenvironment

Ming Yi et al.

Summary: PD-L1 expression is regulated by various factors, impacting the treatment effect and patient selection. Understanding the mechanisms of PD-L1 regulation helps enhance the efficacy of immunotherapy.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Immunology

The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer

Elif Merve Aydin et al.

Summary: The study found that the relationship between H. pylori infection and the expression levels of immune-related genes such as PD-1 and PD-L1 has an impact on the development of gastric immunopathology. The expression of PD-1 and PD-L1 genes significantly increased in patients with gastric ulcer and gastric cancer, showing complex correlations with H. pylori virulence factors.

IMMUNOLOGY LETTERS (2021)

Add to Collection

Article Immunology

PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer

Hao Chen et al.

Summary: The study found that the combination of PD-1 inhibitors and apatinib can significantly inhibit tumor growth in mice with gastric cancer, increase levels of CD4(+)T and CD8(+)T cells in tumor tissue, decrease the proportion of MDSCs, and elevate IL-2, IFN-γ, and TNF-α levels. Additionally, combination therapy also increased tumor tissue necrosis.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Oncology

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

Simon J. Dovedi et al.

Summary: MEDI5752 is a novel monovalent bispecific antibody that enhances the clinical benefits of PD-1 blockade while reducing immune-related adverse events, leading to improved therapeutic outcomes. It represents a significant advancement in the rational design of cancer immunotherapy and shows promising potential in targeting PD-1(+) T cells with enhanced activity compared to conventional mAb combination strategies.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer

Rui Zhao et al.

Summary: This study identified that gastric cancer subtypes with EBV-positive, MSI-H/dMMR, TMB-H, or PIK3CA mutations had enhanced efficacy with PD-L1/PD-1 blockades, sharing similar immune-related gene signatures. Tumor-infiltrating immune cells in these subtypes were mainly M1-like macrophages.

ONCOIMMUNOLOGY (2021)

Add to Collection

Review Cell Biology

Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment

Jacek Baj et al.

Summary: Gastric cancer is a prevalent malignancy worldwide and ranks as the fourth leading cause of cancer-related deaths. The pathogenesis of gastric cancer involves the interaction between genetic and environmental factors, with Helicobacter pylori infection playing a major role. Understanding the mechanisms of H. pylori pathogenicity is crucial for developing eradication strategies to prevent carcinogenesis.

CELLS (2021)

Add to Collection

Article Oncology

Current treatment and recent progress in gastric cancer

Smita S. Joshi et al.

Summary: Gastric cancer is a common cause of cancer death worldwide, with treatment options including systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy. Classification and biomarkers for gastric cancer help in personalized therapy and identifying populations most likely to benefit from immunotherapy and targeted therapy.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Gastroenterology & Hepatology

PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice

Woosook Kim et al.

Summary: In mouse models of gastric cancer, 5-fluorouracil and oxaliplatin reduce numbers of MDSCs to increase the effects of anti-PD-1, promoting tumor infiltration by CD8(+) T cells. However, these chemotherapeutic agents also induce expression of PD-L1 by tumor cells, which contributes to tumor progression. Timing and site of PD-L1 expression are important factors in gastric tumorigenesis and should be considered in therapeutic regimen design.

GASTROENTEROLOGY (2021)

Add to Collection

Article Genetics & Heredity

Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer

Mohammad Amini et al.

Summary: The study found that PD-L1 is significantly hypermethylated in gastric tumors and negatively correlated with PD-L1 expression.

GENE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p

Dong-Liang Chen et al.

Summary: The study highlights the upregulation of circDLG1 in distant metastatic lesions and gastric cancer tissues resistant to anti-PD-1 therapy, correlating with aggressive tumor phenotype and poor prognosis. Ectopic circDLG1 expression promotes proliferation, migration, invasion, and immune evasion of gastric cancer cells. Mechanistically, circDLG1 interacts with miR-141-3p as a miRNA sponge to increase CXCL12 expression, promoting gastric cancer progression and resistance to anti-PD-1 therapy.

MOLECULAR CANCER (2021)

Add to Collection

Article Multidisciplinary Sciences

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian et al.

Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

NATURE (2021)

Add to Collection

Article Oncology

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

Josep Tabernero et al.

Summary: Current guidelines recommend two-drug cytotoxic chemotherapy with a fluoropyrimidine and a platinum-based agent as first-line treatment for advanced gastric cancer. Pembrolizumab monotherapy has shown durable antitumor activity in patients with advanced programmed death ligand 1-positive gastric/gastroesophageal junction adenocarcinoma. Combining pembrolizumab with standard-of-care chemotherapy for advanced or metastatic cancer may enhance clinical outcomes.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: A pooled analysis in the Stomach cancer Pooling (StoP) Project

Giulia Collatuzzo et al.

Summary: The analysis revealed that there is a super-multiplicative interaction between Hp infection and alcohol drinking, as well as high salt intake, while the interaction with smoking and socioeconomic status is weaker. The interactions were more pronounced in individuals with a history of peptic ulcer.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly et al.

Summary: In patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab significantly improved disease-free survival compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Genetics & Heredity

MicroRNA Changes in Gastric Carcinogenesis: Differential Dysregulation during Helicobacter pylori and EBV Infection

Christian Prinz et al.

Summary: Despite medical advances, gastric-cancer mortality remains high in Europe. Infections with H. pylori and EBV are associated with the development of gastric cancer, and miRNAs could serve as promising new tools for early cancer detection. Dysregulation of specific miRNAs, especially miR-155, may potentiate cancer risk in the presence of these infections.

GENES (2021)

Add to Collection

Article Oncology

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Joseph Chao et al.

Summary: This study indicates that MSI-H status may serve as a biomarker for pembrolizumab therapy in advanced G/GEJ cancer patients regardless of the line of therapy.

JAMA ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR

Xiaojia Liu et al.

Summary: TBM-1 negatively regulates PD-L1 level, disrupts PD-1/PD-L1 interaction, and activates tumor-infiltrating T-cell immunity in mice models. Mechanistically, TBM-1 triggers PD-L1 lysosomal degradation in a TFEB-dependent pathway, inhibits mTORC1 activation, and enhances antitumor T-cell immunity in combination with anti-CTLA-4.

ACTA PHARMACEUTICA SINICA B (2021)

Add to Collection

Article Oncology

Gastric epithelial attachment of Helicobacter pylori induces EphA2 and NMHC-IIA receptors for Epstein-Barr virus

Sintayehu Fekadu et al.

Summary: The study found that H. pylori infection increases the efficiency of EBV infection and induces the expression of accessory EBV receptors, promoting the development of EBV-associated gastric cancer.

CANCER SCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Edouard Dantoing et al.

Summary: Anti-PD1/PD-L1 immunotherapy has become a standard of care for NSCLC, with patient selection based on PD-L1 expression and tumor mutational burden. However, mutations in oncogenic drivers can impact efficacy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Medicine, General & Internal

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian et al.

Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.

LANCET (2021)

Add to Collection

Article Cell & Tissue Engineering

MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis

Haiwei Ni et al.

Summary: The study revealed that miR-375 can reduce the stemness of gastric cancer cells by targeting SLC7A11 and triggering ferroptosis. The miR-375/SLC7A11 regulatory axis may serve as a potential therapeutic target to attenuate the stemness of gastric cancer cells.

STEM CELL RESEARCH & THERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model

Shahrokh Abdolahi et al.

Summary: This study demonstrated that a combination therapy of ex vivo activated NK cells and anti-PD-1 treatment resulted in tumor growth inhibition and enhanced immune cell infiltration in a xenograft gastric cancer model. The cytotoxic potential of the treated NK cells against gastric cancer cell lines was evaluated through a series of assays, showing promising anti-tumor effects.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo Negrao et al.

Summary: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry

Yujun Park et al.

Summary: In gastric cancer, the expression of PD-1, LAG3, and TIM3 is positively correlated and associated with better prognosis. There is a significant positive correlation between the expression of different immune checkpoint receptors, with dual or triple ICR expression more frequent in high PD-1 and TIM3 density groups.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Oncology

Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer

Yasunari Ubukata et al.

Summary: Research findings indicate that PD-L1 plays a key role in the initial stages of invasion in gastric cancer, leading to increased rates of lymphatic and vascular invasion. Samples with high PD-L1 expression show more PD-1 and CD163 positive cells, although there is no correlation between PD-L1 expression and levels of these cells.

ONCOLOGY (2021)

Add to Collection

Article Oncology

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Ronan J. Kelly et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment

Anuja Sathe et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer

Yoonjin Kwak et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Review Cell Biology

Immune checkpoint signaling and cancer immunotherapy

Xing He et al.

CELL RESEARCH (2020)

Add to Collection

Article Oncology

Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas

Chan Jin Yoon et al.

GASTRIC CANCER (2020)

Add to Collection

Review Dermatology

Immune checkpoint inhibitor-related dermatologic adverse events

Amaris N. Geisler et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Oncology

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Are Immunohistochemical Markers Useful in Phenotypic Gastric Cancer Classification?

Federica Di Pinto et al.

ONCOLOGY (2020)

Add to Collection

Review Oncology

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target

V Gambardella et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Article Immunology

An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells

Shogo Kumagai et al.

IMMUNITY (2020)

Add to Collection

Article Oncology

CXCL5 promotes gastric cancer metastasis by inducing epithelial-mesenchymal transition and activating neutrophils

Zheying Mao et al.

ONCOGENESIS (2020)

Add to Collection

Article Oncology

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Lin Shen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

PD-1 does not mark tumor-infiltrating CD8+T cell dysfunction in human gastric cancer

Yang Shen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Pharmacology & Pharmacy

Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5

Yang Liu et al.

ACTA PHARMACEUTICA SINICA B (2020)

Add to Collection

Article Oncology

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M. Domchek et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Haiping Jiang et al.

BMC CANCER (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Natural killer cells in cancer biology and therapy

Song-Yang Wu et al.

MOLECULAR CANCER (2020)

Add to Collection

Review Immunology

The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer

Xueke Fan et al.

CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Gastric cancer

Elizabeth C Smyth et al.

LANCET (2020)

Add to Collection

Article Multidisciplinary Sciences

Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions

Juan Liu et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Kohei Shitara et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer

Hye Hyeon Eum et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2020)

Add to Collection

Article Cell Biology

Exosomal miRNA-16-5p Derived From M1 Macrophages Enhances T Cell-Dependent Immune Response by Regulating PD-L1 in Gastric Cancer

Zhengtian Li et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Establishment of an immune microenvironment-based prognostic predictive model for gastric cancer

Luying Wan et al.

LIFE SCIENCES (2020)

Add to Collection

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Surgery

IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer

Yuki Kiyozumi et al.

ANNALS OF SURGERY (2019)

Add to Collection

Article Oncology

EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions

Sho Sasaki et al.

GASTRIC CANCER (2019)

Add to Collection

Article Oncology

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

Yung-Jue Bang et al.

FUTURE ONCOLOGY (2019)

Add to Collection

Article Oncology

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Yung-Jue Bang et al.

GASTRIC CANCER (2019)

Add to Collection

Article Oncology

Autophagy inhibition enhances PD-L1 expression in gastric cancer

Xiaojuan Wang et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Multidisciplinary Sciences

Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma

Atsuhito Nakayama et al.

PLOS ONE (2019)

Add to Collection

Article Microbiology

Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection

Loryn Holokai et al.

PLOS PATHOGENS (2019)

Add to Collection

Article Oncology

Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis

Cong Chen et al.

ONCOIMMUNOLOGY (2019)

Add to Collection

Article Oncology

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Hyun Cheol Chung et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

Mauro Poggio et al.

CELL (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer

In-Hye Ham et al.

MOLECULAR CANCER (2019)

Add to Collection

Article Oncology

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Kohei Shitara et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy

Yuting Liu et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Mechanisms Controlling PD-L1 Expression in Cancer

Jong-Ho Cha et al.

MOLECULAR CELL (2019)

Add to Collection

Article Oncology

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial

Toshihiko Doi et al.

GASTRIC CANCER (2019)

Add to Collection

Article Gastroenterology & Hepatology

Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer

Chao Lin et al.

GUT (2019)

Add to Collection

Review Biochemistry & Molecular Biology

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer

David Vrana et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Oncology

Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells

Sen Li et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Jerome Galon et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection

Article Oncology

Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer

Masahiko Amatatsu et al.

CANCER SCIENCE (2018)

Add to Collection

Review Immunology

Regulation and Function of the PD-L1 Checkpoint

Chong Sun et al.

IMMUNITY (2018)

Add to Collection

Review Oncology

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Julian A. Marin-Acevedo et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara et al.

LANCET (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim et al.

NATURE MEDICINE (2018)

Add to Collection

Article Cell Biology

Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional Apolipoprotein E

Peiming Zheng et al.

CELL DEATH & DISEASE (2018)

Add to Collection

Article Cell Biology

NF-κB/miR-223-3p/ARID1A axis is involved in Helicobacter pylori CagA-induced gastric carcinogenesis and progression

Fenghua Yang et al.

CELL DEATH & DISEASE (2018)

Add to Collection

Article Multidisciplinary Sciences

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion

Jung-Mao Hsu et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article

Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients

Weili Wang et al.

Oncotarget (2018)

Add to Collection

Article Medicine, Research & Experimental

Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts

Xiaofei Ning et al.

MEDICAL SCIENCE MONITOR (2018)

Add to Collection

Article Oncology

Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation

Genevieve P. Hartley et al.

CANCER IMMUNOLOGY RESEARCH (2018)

Add to Collection

Article Oncology

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial

Charles S. Fuchs et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Y. -J. Bang et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Cell Biology

Helicobacter pylori-induced exosomal MET educates tumour-associated macrophages to promote gastric cancer progression

Ying Che et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)

Add to Collection

Article Oncology

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

Yelena Y. Janjigian et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Association between Helicobacter pylori, Epstein-Barr virus, human papillomavirus and gastric adenocarcinomas

Carolina Rosal Teixeira de Souza et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

Add to Collection

Article Oncology

Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer

Hirokazu Kodama et al.

BRITISH JOURNAL OF CANCER (2017)

Add to Collection

Article Gastroenterology & Hepatology

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

Elizabeth D. Thompson et al.

GUT (2017)

Add to Collection

Article Oncology

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

Ruea-Yea Huang et al.

ONCOIMMUNOLOGY (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Polyamine-and NADPH-dependent generation of ROS during Helicobacter pylori infection: A blessing in disguise

Alain P. Gobert et al.

FREE RADICAL BIOLOGY AND MEDICINE (2017)

Add to Collection

Article Gastroenterology & Hepatology

Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway

Ting-ting Wang et al.

GUT (2017)

Add to Collection

Article Medicine, Research & Experimental

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon-Koo Kang et al.

LANCET (2017)

Add to Collection

Article Multidisciplinary Sciences

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

Hiro Sato et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Review Biotechnology & Applied Microbiology

Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development

Mohamed Abozeid et al.

BIOMED RESEARCH INTERNATIONAL (2017)

Add to Collection

Article Oncology

Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer

Liu-sheng Peng et al.

CANCER IMMUNOLOGY RESEARCH (2017)

Add to Collection

Article Oncology

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

Renee N. Donahue et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

Add to Collection

Article Multidisciplinary Sciences

IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma

Ji Wook Moon et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Oncology

Tumor-infiltrating CD4+ T cells in patients with gastric cancer

Long Yuan et al.

CANCER CELL INTERNATIONAL (2017)

Add to Collection

Review Gastroenterology & Hepatology

Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells

Yana Zavros

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2017)

Add to Collection

Article Oncology

Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination

Takahisa Yamaguchi et al.

GASTRIC CANCER (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Arginase 2 deletion leads to enhanced M1 macrophage activation and upregulated polyamine metabolism in response to Helicobacter pylori infection

Dana M. Hardbower et al.

AMINO ACIDS (2016)

Add to Collection

Article Oncology

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study

S. Kanda et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Add to Collection

Article Oncology

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

Jin Won Kim et al.

GASTRIC CANCER (2016)

Add to Collection

Review Genetics & Heredity

Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells

Shosuke Kawanishi et al.

GENES AND ENVIRONMENT (2016)

Add to Collection

Article Gastroenterology & Hepatology

The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis

Ami Ben Ya ' acov et al.

BMC GASTROENTEROLOGY (2015)

Add to Collection

Article Medicine, Research & Experimental

TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients

Joe-Marc Chauvin et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

Add to Collection

Article Oncology

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Razvan Cristescu et al.

NATURE MEDICINE (2015)

Add to Collection

Article Cell Biology

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

Julia Cuende et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Add to Collection

Article Oncology

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

Ruea-Yea Huang et al.

ONCOTARGET (2015)

Add to Collection

Article Gastroenterology & Hepatology

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

Suling J. Lin et al.

GUT (2015)

Add to Collection

Review Biochemistry & Molecular Biology

Helicobacter pylori infection and stem cells at the origin of gastric cancer

E. Bessede et al.

ONCOGENE (2015)

Add to Collection

Article Multidisciplinary Sciences

Comprehensive molecular characterization of gastric adenocarcinoma

Adam J. Bass et al.

NATURE (2014)

Add to Collection

Article Gastroenterology & Hepatology

Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil

Zhengdeng Lei et al.

GASTROENTEROLOGY (2013)

Add to Collection

Review Immunology

Th17 cell development: from the cradle to the grave

Luis A. Zuniga et al.

IMMUNOLOGICAL REVIEWS (2013)

Add to Collection

Review Immunology

The Th17 family: flexibility follows function

Rajatava Basu et al.

IMMUNOLOGICAL REVIEWS (2013)

Add to Collection

Article Multidisciplinary Sciences

Epstein Barr Virus and Helicobacter pylori Co-Infection Are Positively Associated with Severe Gastritis in Pediatric Patients

Maria G. Cardenas-Mondragon et al.

PLOS ONE (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

Nikolaos Patsoukis et al.

SCIENCE SIGNALING (2012)

Add to Collection

Article Cell Biology

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Janis M. Taube et al.

SCIENCE TRANSLATIONAL MEDICINE (2012)

Add to Collection

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection

Article Multidisciplinary Sciences

Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+ T Cells

Sujit V. Janardhan et al.

PLOS ONE (2011)

Add to Collection

Article Immunology

Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8+ T Cells by Rapid Induction of Multiple Inhibitory Receptors

Shiki Takamura et al.

JOURNAL OF IMMUNOLOGY (2010)

Add to Collection

Article Multidisciplinary Sciences

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

Junko Matsuzaki et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Add to Collection

Article Oncology

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN

Zvi G. Fridlender et al.

CANCER CELL (2009)

Add to Collection

Article Immunology

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

Manish J. Butte et al.

IMMUNITY (2007)

Add to Collection

Article Immunology

Expression of B7-H1 on gastric epithelial cells:: Its potential role in regulating T cells during Helicobacter pylori infection

Soumita Das et al.

JOURNAL OF IMMUNOLOGY (2006)

Add to Collection

Article Cell Biology

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

Changping Wu et al.

ACTA HISTOCHEMICA (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.